Table 2:
comparative analysis of individuals according to their RT-PCR result during the study period
| Age ≥ 60 | age 40–59 | age 18–39 | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| negative | positive | p val. | OR | negative | positive | p val. | OR | negative | positive | p val. | OR | |
| N | 8,984 | 201 | 11,276 | 222 | 13,125 | 185 | ||||||
| age, mean (SD) | 69.24 (7.32) | 70.25 (7.86) | 0.055 | 49.36 (5.74) | 48.75 (5.58) | 0.117 | 28.97 (6.11) | 30.03 (6.12) | 0.019 | |||
| sex female, N (%) | 4,645 (51.7 %) | 95 (47.3 %) | 0.225 | 0.84 | 5,620 (49.8 %) | 115 (51.8 %) | 0.588 | 1.08 | 6,062 (46.2 %) | 93 (50.3 %) | 0.299 | 1.18 |
| Socio-economic status, mean (SD) | 10.94 (3.44) | 11.21 (3.23) | 0.274 | 10.16 (3.70) | 10.77 (3.48) | 0.021 | 9.11 (3.80) | 10.16 (3.45) | <0.001 | |||
| time since 2nd dose of vaccine in days, median [IQR] | 167 [147179] | 175 [165–182] | <0.001 | 151 [128–166] | 159 [146–170] | <0.001 | 128 [105–147] | 141 [128–153] | <0.001 | |||
| more than 146 days since vaccination, N (%) | 6,839 (76.1 %) | 182 (90.5 %) | <0.001 | 3.00 | 6,433 (57.1%) | 167 (75.2 %) | <0.001 | 2.29 | 3,518 (26.8 %) | 72 (38.9 %) | <0.001 | 1.74 |
| time between 1st and 2nd dose of vaccine in days, median [IQR] | 21 [21–21] | 21 [21–21] | 0.190 | 21 [21–21] | 21 [21–21] | 0.575 | 21 [21–21] | 21 [21–21] | 0.123 | |||
| diabetes mellitus, N (%) | 2,927 (32.6 %) | 72 (35.8 %) | 0.361 | 1.15 | 1,166 (10.3 %) | 20 (9.0 %) | 0.579 | 0.86 | 162 (1.2 %) | 4 (2.2 %) | 0.297 | 1.77 |
| hypertension, N (%) | 5,517 (61.4 %) | 131 (65.2 %) | 0.305 | 1.18 | 2,092 (18.6 %) | 35 (15.8 %) | 0.337 | 0.82 | 313 (2.4 %) | 7 (3.8 %) | 0.219 | 1.61 |
| asthma, N (%) | 865 (9.6 %) | 21 (10.4 %) | 0.716 | 1.10 | 852 (7.6 %) | 16 (7.2 %) | 1.000 | 0.95 | 1,226 (9.3 %) | 16 (8.6 %) | 0.898 | 0.92 |
| COPD, N (%) | 1,093 (12.2 %) | 27 (13.4 %) | 0.585 | 1.12 | 404 (3.6 %) | 5 (2.3 %) | 0.361 | 0.62 | 88 (0.7 %) | 1 (0.5 %) | 1.000 | 0.81 |
| ischemic heart disease, N (%) | 1,631 (18.2 %) | 37 (18.4 %) | 0.926 | 1.02 | 352 (3.1%) | 6 (2.7 %) | 1.000 | 0.86 | 11 (0.1 %) | 1 (0.5 %) | 0.155 | 6.48 |
| solid tumor, N (%) | 1,446 (16.1 %) | 28 (13.9 %) | 0.496 | 0.84 | 486 (4.3 %) | 6 (2.7 %) | 0.313 | 0.62 | 116 (0.9 %) | 3 (1.6 %) | 0.230 | 1.85 |
| chronic kidney disease, N (%) | 602 (6.7 %) | 20 (10.0 %) | 0.086 | 1.54 | 91 (0.8 %) | 1 (0.5 %) | 1.000 | 0.56 | 34 (0.3 %) | 2 (1.1%) | 0.089 | 4.21 |
OR: odds ratio; SD: Standard Deviation; IQR: Interquartile range; COPD: Chronic Obstructive Pulmonary Disease